MX2009007005A - Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana. - Google Patents

Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana.

Info

Publication number
MX2009007005A
MX2009007005A MX2009007005A MX2009007005A MX2009007005A MX 2009007005 A MX2009007005 A MX 2009007005A MX 2009007005 A MX2009007005 A MX 2009007005A MX 2009007005 A MX2009007005 A MX 2009007005A MX 2009007005 A MX2009007005 A MX 2009007005A
Authority
MX
Mexico
Prior art keywords
6alkyl
6alkyloxy
polyhaloc1
amino
6alkenyl
Prior art date
Application number
MX2009007005A
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
Celine Isabelle Mordant
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2009007005A publication Critical patent/MX2009007005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de replicación de VIH de fórmula (I) (ver fórmula (I)) R1 es hidrógeno; arilo; formilo; alquilcarbonilo de C1-6; alquilo de C1-6; alquiloxicarbonilo de C1-6; R2, R3, R6 y R7 son hidrógeno; hidroxi; halo; cicloalquilo de C3-7; alquiloxi de C1-6; carboxilo; alquiloxicarbonilo de C1-6; ciano; nitro; amino; mono o dialquilamino de C1-6; polihaloalquilo de C1-6; polihaloalquiloxi de C1-6; -C(=O)R9; alquilo de C1-6 opcionalmente sustituido, alquenilo de C2-6 o alquinilo de C2-6; R4 y R8 son hidroxi; halo; cicloalquilo de C3-7; alquiloxi de C1-6; carboxilo; alquiloxicarbonilo de C1-6; formilo; ciano; nitro; amino; mono o dialquilamino de C1-6; polihaloalquilo de C1-6; polihaloalquiloxi de C1-6; -C(=O)R9; ciano; -S(=O)rR9, -NH-S(=O)2R9 -NHC(=O)H; -C(=O)NHNH2; -NHC(=O)R9; Het; -Y-Het; alquilo de C1-6 opcionalmente sustituido, alquenilo de C2-6 o alquinilo de C2-6; R5 es piridilo, -C(=O)NR5aR5b; -CH(OR5c)R5d, -CH2-NR5eR5f; -CH=NOR5a; -CH2-O-alquenilo C2-6; -CH2-O-P(=O)(OR5g)2; -CH2-O-C(=O)-NH2; -C(=O)R5d; X es -NR1, -O-, -CH2-, -S-; composiciones farmacéuticas que contienen estos compuestos como ingrediente activo y procedimientos para la preparación de dichos compuestos y composiciones.
MX2009007005A 2006-12-29 2007-12-28 Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana. MX2009007005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127325 2006-12-29
PCT/EP2007/064605 WO2008080964A1 (en) 2006-12-29 2007-12-28 Hiv inhibiting 6-substituted pyrimidines

Publications (1)

Publication Number Publication Date
MX2009007005A true MX2009007005A (es) 2009-07-09

Family

ID=39283877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007005A MX2009007005A (es) 2006-12-29 2007-12-28 Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana.

Country Status (13)

Country Link
US (1) US9006243B2 (es)
EP (1) EP2114901B1 (es)
JP (1) JP5185283B2 (es)
KR (1) KR20090094073A (es)
CN (1) CN101573343B (es)
AU (1) AU2007341227C1 (es)
BR (1) BRPI0720858B8 (es)
CA (1) CA2674178C (es)
DK (1) DK2114901T3 (es)
EA (1) EA020772B1 (es)
ES (1) ES2470570T3 (es)
MX (1) MX2009007005A (es)
WO (1) WO2008080964A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
ATE542802T1 (de) 2004-09-30 2012-02-15 Tibotec Pharm Ltd Hiv-inhibierende 5-substituierte pyrimidine
ATE520680T1 (de) 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-heterocyclylpyrimidine
MX2007010051A (es) * 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
MX2008012576A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
MX2009007006A (es) 2006-12-29 2009-07-09 Tibotec Pharm Ltd Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN102083800A (zh) 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2011017079A1 (en) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Process for the preparation and purification of etravirine and intermediates thereof
WO2012021444A1 (en) 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN102260215A (zh) * 2011-05-13 2011-11-30 复旦大学 一种二芳基嘧啶类衍生物及其制备方法和用途
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
EP2825041B1 (en) 2012-03-15 2021-04-21 Celgene CAR LLC Solid forms of an epidermal growth factor receptor kinase inhibitor
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CN102731414B (zh) * 2012-07-04 2014-11-26 宁波九胜创新医药科技有限公司 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法
CN102718720B (zh) * 2012-07-04 2015-01-07 宁波九胜创新医药科技有限公司 4-[(4,6-二氯-2-嘧啶基)氨基]苯腈的制备方法
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP2016509012A (ja) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｅｒｋ阻害剤およびそれらの使用
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
JP6531958B2 (ja) 2017-04-17 2019-06-19 千住金属工業株式会社 フラックス組成物及びソルダペースト組成物
JP7331579B2 (ja) 2018-09-28 2023-08-23 荒川化学工業株式会社 鉛フリーはんだフラックス、鉛フリーソルダペースト

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
AU725204B2 (en) 1995-11-23 2000-10-05 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
EP0945443B9 (en) 1998-03-27 2003-08-13 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
AU762523C (en) * 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
WO2002068415A1 (en) 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
JP2006508145A (ja) 2002-11-15 2006-03-09 テイボテク・フアーマシユーチカルズ・リミテツド 抗感染化合物としての置換インドールピリジニウム
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR20070057798A (ko) * 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
ATE520680T1 (de) 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-heterocyclylpyrimidine
ATE542802T1 (de) 2004-09-30 2012-02-15 Tibotec Pharm Ltd Hiv-inhibierende 5-substituierte pyrimidine
US20090124644A1 (en) * 2005-01-27 2009-05-14 Janssen Pharmaceutica N.V. Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives
RU2452737C2 (ru) * 2006-03-30 2012-06-10 Тиботек Фармасьютикалз Лтд. 5-(гидроксиметилен- и аминометилен)замещенные пиримидины, ингибирующие вич
MX2008012576A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
MX2009007006A (es) 2006-12-29 2009-07-09 Tibotec Pharm Ltd Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.

Also Published As

Publication number Publication date
AU2007341227A1 (en) 2008-07-10
EP2114901A1 (en) 2009-11-11
KR20090094073A (ko) 2009-09-03
BRPI0720858A2 (pt) 2014-07-01
WO2008080964A1 (en) 2008-07-10
US9006243B2 (en) 2015-04-14
AU2007341227B2 (en) 2013-04-18
CA2674178A1 (en) 2008-07-10
JP5185283B2 (ja) 2013-04-17
EA200970655A1 (ru) 2009-12-30
BRPI0720858B8 (pt) 2021-05-25
AU2007341227C1 (en) 2013-08-29
CN101573343A (zh) 2009-11-04
JP2010514735A (ja) 2010-05-06
ES2470570T3 (es) 2014-06-24
US20100016317A1 (en) 2010-01-21
DK2114901T3 (da) 2014-06-30
EA020772B1 (ru) 2015-01-30
BRPI0720858B1 (pt) 2020-01-21
CA2674178C (en) 2015-11-10
EP2114901B1 (en) 2014-04-09
CN101573343B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
MX2009007005A (es) Pirimidinas 6-sustituidas que inhiben el virus de inmunodeficiencia humana.
MX2009007006A (es) Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.
DK1442019T3 (da) Amidderivater som glycogensynthasekinase 3- beta-inhibitorer
MXPA04004178A (es) Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
AP1610A (en) HIV replication inhibiting pyrimidines.
TW200626574A (en) HIV inhibiting 5-heterocyclyl pyrimidines
TW200626560A (en) HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
MY176490A (en) Pyrimidine derivatives for the prevention of hiv infection
TW200510339A (en) HIV replication inhibiting pyrimidines and triazines
MX2007005159A (es) Derivados de pirimidina biciclicos inhibidores del vih.
MY148322A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
MY148634A (en) Pyridazinone derivatives
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
UA100846C2 (uk) Сполуки та композиція як інгібітори протеїнкінази
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
TW200833694A (en) Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety
TW200517106A (en) Sustained release pharmaceutical compositions
RS51435B (en) 2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINE INHIBITING HIV
WO2006075023A3 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
MY140571A (en) Mercaptoimidazoles as ccr2 receptor antagonists
TW200606155A (en) Mercaptoimidazoles as CCR2 receptor antagonists
WO2004007498A3 (en) 3-phenyl analogs of toxoflavine as kinase inhibitors
CY1125571T1 (el) Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv

Legal Events

Date Code Title Description
FG Grant or registration